Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 8/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22308111 | 0.80 | PDE3B (0.58) | PDE3BPDE3AMEN1KMT2ALMNA | |
| SCHEMBL21810330 | 0.78 | PDE3B (0.50) | PDE3BPDE3AMEN1KMT2ALMNA | |
| SCHEMBL21810002 | 0.76 | PDE3B (0.55) | PDE3BPDE3AMEN1KMT2ALMNA | |
| SCHEMBL21810200 | 0.74 | PDE3B (0.47) | PDE3BPDE3AGAAMAPK1ALDH1A1 | |
| SCHEMBL6475634 | 0.74 | MEN1 (0.48) | MEN1KMT2AALOX5 | |
| SCHEMBL22308112 | 0.73 | PDE3B (0.60) | PDE3BPDE3AMEN1KMT2ALMNA | |
| SCHEMBL6477062 | 0.72 | HPGD (0.43) | MEN1KMT2ALMNAALOX5ALDH1A1 | |
| SCHEMBL5281256 | 0.72 | ALOX5 (0.43) | PDE3BPDE3AMEN1KMT2AGAA | |
| SCHEMBL31486653 | 0.72 | GAA (0.56) | PDE3BPDE3AMEN1KMT2ALMNA | |
| SCHEMBL21809722 | 0.69 | PDE3B (0.43) | PDE3BPDE3ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936632-B2 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | PTGS1, PTGS2, PTGER1 | PDE3B 673/4885PDE3A 658/4885MEN1 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.